• ML133 HCl: Precision Potassium Channel Inhibitor for Kir2.1

  2026-05-26

  ML133 HCl stands out as a potent and selective potassium channel inhibitor, enabling high-precision studies of Kir2.1 channel function in cardiovascular and pulmonary artery smooth muscle cell (PASMC) research. Its specificity accelerates discovery in vascular remodeling and pulmonary hypertension models while minimizing off-target effects.

• Dextran Microgel Nanotherapeutics for Oral Colon Cancer Ther

  2026-05-26

  This article analyzes a recent study presenting a hierarchically targeted oral delivery system using dextran microgels loaded with cisplatin and SPION-lipid nanoparticles for localized colon cancer treatment. The innovation lies in dual-stage targeting and controlled release, which significantly enhances colonic retention, cellular uptake, and therapeutic efficacy, providing new directions for oral nanomedicine in colorectal cancer research.

• FXR–KLF11 Axis Suppresses JAK2/STAT3 to Protect Against CI-A

  2026-05-25

  This study establishes the FXR–KLF11 axis as a critical regulatory pathway in protecting against contrast-induced acute kidney injury (CI-AKI). By demonstrating that FXR activation upregulates KLF11 and suppresses the JAK2/STAT3 pathway, the research offers mechanistic insights with translational potential for renal inflammation mitigation.

• Alisol A Regulates Cholesterol and Autophagy in Vascular Cog

  2026-05-25

  The reference study reports that Alisol A ameliorates vascular cognitive impairment (VCI) through coordinated regulation of cholesterol metabolism and mitophagy via the AMPK/NAMPT/SIRT1 axis. These findings provide mechanistic insight into VCI pathogenesis and highlight NAMPT as a potential therapeutic target for atherosclerosis-related cognitive decline.

• Benzyl-activated Streptavidin Magnetic Beads (SKU: K1301): T

  2026-05-24

  Benzyl-activated Streptavidin Magnetic Beads (SKU: K1301) provide an efficient solution for capturing and purifying biotinylated molecules from complex samples, minimizing non-specific interactions and streamlining separation workflows. Suitable for protein, nucleic acid, and immunoprecipitation applications, these beads are not recommended for untested or highly atypical sample matrices without additional validation.

• AICAR in Metabolic Research: Protocols, Innovations, and Tro

  2026-05-23

  AICAR (5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside) empowers metabolic researchers with robust AMPK activation, enabling precise dissection of energy homeostasis and inflammation pathways. This article distills cutting-edge experimental workflows, evidence-based troubleshooting, and the latest protocol refinements to help scientists harness AICAR's full potential in metabolic disease and cellular stress models.

• Sorafenib (BAY-43-9006): Multikinase Inhibitor in ATRX-Defic

  2026-05-22

  Explore how Sorafenib, a leading multikinase inhibitor, advances cancer biology research by uniquely targeting ATRX-deficient tumor models. This article delivers an in-depth, evidence-driven perspective on optimizing Sorafenib assays for mechanistic and translational studies.

• Synthetic Lethality via Mcl-1 and BCL-XL/BCL-2 Inhibition in

  2026-05-22

  The reference study demonstrates that concurrent epigenetic suppression of Mcl-1 and pharmacological inhibition of BCL-XL/BCL-2 induces synthetic lethality and robust apoptosis in glioblastoma models. This combined strategy reveals new opportunities for overcoming apoptotic resistance in GBM and guides the rational use of selective BCL-XL inhibitors in research.

• Apicidin Disrupts Oocyte Maturation by Targeting HDAC Functi

  2026-05-21

  This study uncovers how Apicidin, a selective histone deacetylase inhibitor and emerging mycotoxin, impairs oocyte quality by disrupting meiotic apparatus assembly and altering histone acetylation. The findings highlight crucial reproductive toxicology concerns and provide mechanistic insight for both risk assessment and laboratory modeling.

• Axitinib (AG 013736): Precision Angiogenesis Inhibition Work

  2026-05-21

  Axitinib (AG 013736) from APExBIO is a benchmark selective VEGFR inhibitor that enables reproducible angiogenesis and tumor suppression studies. This guide translates recent advances in in vitro drug response phenotyping into practical, workflow-driven protocols for cancer biology research.

• ERRα Acetylation Drives RCC Progression via Autophagy Regula

  2026-05-20

  This study uncovers a novel mechanism wherein hypoxia-induced acetylation of ERRα enhances its oncogenic activity in renal cell carcinoma (RCC) by promoting autophagosome-lysosome fusion and sustaining autophagy flux. These findings offer mechanistic insight into RCC progression and suggest new avenues for overcoming sunitinib resistance and targeting autophagy pathways.

• PTX3 Protects Against Glucocorticoid-Induced ONFH via TLR4/N

  2026-05-20

  Li et al. identify pentraxin 3 (PTX3) as a critical modulator that protects against glucocorticoid-induced osteonecrosis of the femoral head (ONFH) by engaging the TLR4/NF-κB/FGF21 signaling axis. Their study delineates mechanistic insight into how PTX3 supplementation preserves bone integrity under glucocorticoid stress, offering a foundation for future therapeutic strategies targeting ER stress and inflammatory bone pathology.

• TG003 Cdc2-like Kinase Inhibitor: Workflows for Splicing Mod

  2026-05-19

  TG003 is redefining research on alternative splicing, platinum resistance, and exon-skipping therapies with its potent, selective inhibition of Clk kinases. This article details experimental strategies, optimization tactics, and troubleshooting insights, leveraging TG003’s unique profile for robust, reproducible results.

• Z-VEID-FMK: Caspase-6 Inhibitor Workflows in Apoptosis Resea

  2026-05-19

  Z-VEID-FMK empowers researchers to dissect caspase-6-dependent apoptosis with precision—enabling reproducible results in neuronal, immune, and cancer models. With robust protocol guidance and troubleshooting strategies, this article unlocks data-driven workflow enhancements for advanced cell death studies.

• IEM 1460: Advanced Workflows for AMPA Receptor Blocker Resea

  2026-05-18

  IEM 1460 stands out as a highly selective AMPA receptor blocker, empowering researchers to unravel synaptic mechanisms and neuroprotection strategies with unmatched specificity. This guide translates recent breakthroughs and hands-on troubleshooting into actionable protocols for reproducible, high-impact neuroscience assays.

14685 records 1/979 page Next 12345 下5页 Last page